Clinical Trial: Study Evaluating the Safety, Immunogenicity and Tolerability of Meningococcal Group B Vaccine in Healthy Adults

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title: A Randomized, Placebo-Controlled, Double Blind, Phase 1 Trial of the Safety, Immunogenicity, and Tolerability of Ascending Doses of Meningococcal Group B rLP2086 Vaccine in Healthy Adults

Brief Summary: To determine the safety & immunogenicity of a potential vaccine against meningococcal B disease

Detailed Summary:
Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer

Current Primary Outcome: Local & systemic safety throughout the trial

Original Primary Outcome: Same as current

Current Secondary Outcome: Evidence of an immune response 1 month after dose 2 & 1 month after dose 3

Original Secondary Outcome: Same as current

Information By: Wyeth is now a wholly owned subsidiary of Pfizer

Dates:
Date Received: February 24, 2006
Date Started: March 2006
Date Completion:
Last Updated: December 3, 2007
Last Verified: December 2007